三鑫医疗(300453) - 2025 Q4 - 年度业绩

Financial Performance - Total operating revenue for 2025 reached CNY 164,009.37 million, an increase of 9.31% compared to the previous year[4] - Net profit attributable to shareholders was CNY 26,248.93 million, reflecting a growth of 15.43% year-on-year[4] - Net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 23,926.34 million, up 14.01% from the previous year[4] - Basic earnings per share increased to CNY 0.5076, a rise of 14.95% compared to the same period last year[4] Assets and Equity - Total assets at the end of the reporting period were CNY 242,703.91 million, a 9.19% increase from the beginning of the period[5] - Shareholders' equity attributable to the company reached CNY 145,584.51 million, growing by 9.95% from the start of the period[5] - Net asset value per share increased to CNY 2.79, reflecting a growth of 10.28% compared to the beginning of the period[5] Strategic Focus - The company focused on strategic development goals, product innovation, and international market expansion to enhance competitiveness and profitability[5] Financial Condition - The financial condition of the company is stable, with significant growth in asset scale and shareholder equity[5] - The financial data presented is preliminary and subject to audit, with final figures to be disclosed in the 2025 annual report[7]